A few years ago, there was much talk of the “patent cliff” facing blockbuster drugs like Lipitor and other huge name-brand drugs. The “patent cliff” may have spelled the end…
The post Why Generic Drug Makers May Benefit from 505(b)(2) Approval appeared…
Why Generic Drug Makers May Benefit from 505(b)(2) Approval Read Post »
This article was originally published by Li Du in BMC Medical Ethics 2018 19:29 under a creative commons license. Abstract Background The patenting of human genes has been the subject…
The post Patenting human genes: Chinese academic articles’ portraya…
Patenting human genes: Chinese academic articles’ portrayal of gene patents Read Post »
Drug development is one of the world’s most high-risk / high-reward industries, with the vast majority of drugs created never making it to market. Of those that do make it…
The post The 505(b)(2) Drug Patent Approval Process: Uses and Potential Advanta…
The 505(b)(2) Drug Patent Approval Process: Uses and Potential Advantages Read Post »
Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly…
The post Pharmaceutical Portfo…
Pharmaceutical Portfolio Management Reading List Read Post »
Artificial intelligence (AI) is the development within computer systems of the ability to perform tasks that have traditionally required human intelligence. Examples of AI applications include visual perception, speech recognition,…
The post How Artifi…
How Artificial Intelligence Will Affect Healthcare and Drug Prices Read Post »
This paper was originally published by Dibyendu Dana, Satishkumar V. Gadhiya, Luce G. St. Surin, David Li, Farha Naaz, Quaisar Ali, Latha Paka, Michael A. Yamin, Mahesh Narayan, Itzhak D. Goldberg…
The post Deep Learning in Drug Discovery and Medicine …
Deep Learning in Drug Discovery and Medicine – Scratching the Surface Read Post »
This article was originally published by Christopher M. Holman in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-nc-sa/4.0/). Despite the impor…
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection Read Post »
The US pharmaceutical market, together with those of Canada and Mexico, make more than half the global pharmaceutical. The US alone is the world’s largest and it represents 45 percent of…
The post FDA Approval of New Drugs One of Many Goals for Drug Ma…
FDA Approval of New Drugs One of Many Goals for Drug Manufacturers Read Post »
This article was originally published by James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr & David A Brindley in Nature Biotechnology v35, pp 210–214 (2017) under a creative…
The post Evidence of insufficient quality of reporting in patent l…
Evidence of insufficient quality of reporting in patent landscapes in the life sciences Read Post »
This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
The post Indian pharmaceutical patent prosecutio…
Indian pharmaceutical patent prosecution: The changing role of Section 3(d) Read Post »